BCAB (BioAtla, Inc. Common Stock) Stock Analysis - AI Report

BioAtla, Inc. Common Stock (BCAB) is a publicly traded Healthcare sector company. As of May 21, 2026, BCAB trades at $3.62 with a market cap of $6.50M and a P/E ratio of -0.73. BCAB moved -3.36% today. Year to date, BCAB is -82.97%; over the trailing twelve months it is -81.51%. Its 52-week range spans $3.26 to $126.25. Rallies surfaces BCAB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the AI research view on BCAB?

Rallies AI research for BCAB combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.

BCAB Key Metrics

Key financial metrics for BCAB
MetricValue
Price$3.62
Market Cap$6.50M
P/E Ratio-0.73
EPS$-4.97
Dividend Yield0.00%
52-Week High$126.25
52-Week Low$3.26
Volume0
Avg Volume0
Revenue (TTM)$2.00M
Net Income$-50.62M
Gross Margin0.00%

Latest BCAB News

BCAB Analyst Consensus

BCAB analyst coverage data. Average price target: $0.00.

Common questions about BCAB

What is the AI research view on BCAB?
Rallies AI research for BCAB combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for BCAB?
Rallies AI research for BCAB combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is BCAB research on Rallies investment advice?
No. Rallies provides research, data, and educational context for BCAB. It does not provide personalized investment advice.
BCAB

BCAB